News | June 08, 2026
Roche signs up to $2.3 billion deal with Nurix for BTK degrader Bexobrutideg
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
The program expected to commence in August 2026 will be offered across multiple specialised areas with an intake of 20-30 students per course
Built on Snowflake Cortex AI, the agent enables representatives to generate comprehensive pre-call plans through a single conversational interface
Amitabh Dube and Sheetal Arora named Co-Chairmen for the forthcoming term
The addition of the Halcyon system represents a significant milestone in the hospital’s oncology services
Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe (PFS) presentations
The webinar on World Environment Day brought together scientists, policymakers, industry representatives, and researchers to discuss the role of biotech and biomanufacturing in addressing climate change and advancing sustainable development
Rahul brings over 17 years of experience in human resources leadership across the healthcare, banking, information technology, and FMCG sectors
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
Anbalagan has led end-to-end product development programs from concept to commercialization, with a strong focus on regulatory compliance, process scalability, and manufacturing readiness
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
